A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer

1. Rixe, O.
2. Franco, S.X.
3. Yardley, D.A.
4. Johnston, S.R.
5. Martin, M.
6. Arun, B.K.
7. Letrent, S.P.
8. Rugo, H.S.